Valcyte 50 mg/ml powder for oral solution
Authorisation PA2239/023/002 · CHEPLAPHARM Arzneimittel GmbH
- Licence holder
- CHEPLAPHARM Arzneimittel GmbH (all products →)
- Active substance
- Valganciclovir hydrochloride
- Clinical trials
- 6 clinical trials →
- Dosage form
- Powder for oral solution
- Route of administration
- Oral use
- ATC codes
- J05AB, J05AB14
- First authorised
- 15/08/2008
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Valganciclovir hydrochloride: supply and approvals
3 authorised products on the HPRA list contain Valganciclovir hydrochloride. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- 1 supply notice, e.g. Valgapan 50 mg/ml Pulver zur Herstellung einer Lösung zum Einnehmen (17 Sep 2026 to 1 Dec 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 18 years (since 15 August 2008). The HPRA list marks it as marketed in Ireland.
Other medicines with Valganciclovir hydrochloride in Ireland
2 other products on the HPRA list contain Valganciclovir hydrochloride, from 2 licence holders; 2 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Valcyte 450 mg film-coated tablets | CHEPLAPHARM Arzneimittel GmbH | National authorisation (PA) | Marketed |
| Valganciclovir Accord 450 mg film-coated tablets | Accord Healthcare Ireland Ltd. | National authorisation (PA) | Marketed |
Other substances in ATC group J05AB
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 6 other active substances share the group J05AB with this product:
Aciclovir (10) · Famciclovir (9) · Valaciclovir (6) · Ganciclovir (1) · Valaciclovir hydrochloride (1) · Acyclovir (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
CHEPLAPHARM Arzneimittel GmbH holds 74 products on the HPRA list, with 33 different active substances; 44 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.